Celgene

Jefferies is maintaining its $68 PT on shares of Celgene Corporation (NASDAQ: CELG). “We had an opportunity to speak to physicians regarding the use of Revlimid maintenance and Abraxane for non-small cell lung carcinoma (NSCLC),” Jefferies writes. “Feedback was highly positive on Revlimid, but...

Piper Jaffray is out with its report today on Celgene Corp. (NASDAQ: CELG), raising its PT from $81 to $82. In a note to clients, Piper Jaffray writes, "The FDA has granted Fast Track Designation for Onyx's carfilzomib in relapse/refractory multiple myeloma patients, allowing accelerated filing on...

Jefferies published its research report today on Celgene Corp. (NASDAQ: CELG) in regards to Revlimid maintenance. In a note to clients, Jefferies writes, "We continue to believe that Revlimid maintenance could become part of the gold standard treatment strategy for front-line myeloma. Significant...

Jefferies has published its research report on Celgene (NASDAQ: CELG) after concern was raised regarding secondary malignancies during Revlimid maintenance therapy. In a note to clients, Jefferies writes, "Both investigators to whom we spoke were still favorable on the overall risk benefit profile...

J.P. Morgan recently attended Celgene Corporation's (NASDAQ: CELG) ASH 2010 analyst event, where the hot topic of conversation was related to malignancies observed in the CALGB study presented earlier today (25 total; Revlimid arm-15, placebo-6, prior to randomization-4). “Indeed, while this is...

In a Piper Jaffray research report this morning Alexion (NasdaqGS: ALXN) and Celgene (NasdaqGS: CELG) are both reviewed as they are awaiting approval for Soliris and Revlimid Maintenance respectively. Alexion has an Overweight rating with a price target of $86. Alexion closed Monday at $72.73....